Danazol ( DrugBank: Danazol )
5 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 60 | 再生不良性貧血 | 3 |
| 63 | 特発性血小板減少性紫斑病 | 1 |
| 64 | 血栓性血小板減少性紫斑病 | 1 |
| 65 | 原発性免疫不全症候群 | 2 |
| 285 | ファンコニ貧血 | 1 |
60. 再生不良性貧血
臨床試験数 : 245 / 薬物数 : 318 - (DrugBank : 86) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 166
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000041485 | 2021-01-01 | 2020-12-27 | Efficacy of Danazol after no response to cyclosporin in transfusion independent aplastic anemia: a prospective study | Efficacy of Danazol after no response to cyclosporin in transfusion independent aplastic anemia: a prospective study | transfusion independent aplastic anemia | experimental group:Cyclosporine combined with danazol;control group:Cyclosporine; | Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College | NULL | Recruiting | Both | experimental group:152;control group:76; | Phase 4 | China | ||
| 2 | ChiCTR1900027553 | 2019-11-28 | 2019-11-18 | Clinical therapies for patients in subtypes of non-severe aplastic anemia | Clinical therapies for patients in subtypes of non-severe aplastic anemia | non-severe aplastic anemia | early NSAA:Cyclosporine;moderate NSAA1:Cyclosporine;moderate NSAA2:Cyclosporine+Danazol;TD NSAA:CSA+TPO+G-CSF; | Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences | NULL | Pending | 18 | 85 | Both | early NSAA:89;moderate NSAA1:37;moderate NSAA2:39;TD NSAA:325; | China | |
| 3 | NCT01441037 (ClinicalTrials.gov) | July 19, 2011 | 24/9/2011 | Danazol for Genetic Bone Marrow and Lung Disorders | Male Hormones for Telomere Related Diseases | Aplastic Anemia | Drug: Danazol | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Completed | 2 Years | N/A | All | 27 | Phase 1/Phase 2 | United States |
63. 特発性血小板減少性紫斑病
臨床試験数 : 391 / 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1800016177 | 2018-07-01 | 2018-05-17 | Withdraw by the investigator Efficacy and safety of danazol combined with low-dose glucocorticoids in the treatment of refractory/recurrent primary immune thrombocytopenia: a multicenter, single arm, prospective and open clinical study | Efficacy and safety of danazol combined with low-dose glucocorticoids in the treatment of refractory/recurrent primary immune thrombocytopenia: a multicenter, single arm, prospective and open clinical study prospective and open clinical study | Immune thrombocytopenic purpura | experimental group:danazol combined with low-dose glucocorticoids ; | Second Affiliated Hospital of Dalian Medical University | NULL | Temporary halt | 40 | 90 | Female | experimental group:30; | N/A | China |
64. 血栓性血小板減少性紫斑病
臨床試験数 : 92 / 薬物数 : 85 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 76
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00953771 (ClinicalTrials.gov) | October 2008 | 4/8/2009 | Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) | Phase II Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura | Thrombotic Thrombocytopenic Purpura | Drug: Danazol | Icahn School of Medicine at Mount Sinai | Beth Israel Medical Center | Terminated | 18 Years | N/A | All | 8 | Phase 2 | United States |
65. 原発性免疫不全症候群
臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04638517 (ClinicalTrials.gov) | September 7, 2021 | 4/11/2020 | The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis | The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis | Telomere Shortening;Telomere Disease;Dyskeratosis Congenita;Pulmonary Fibrosis | Drug: Danazol;Drug: Placebo | The University of Queensland | NULL | Recruiting | 5 Years | N/A | All | 50 | Phase 2 | Australia |
| 2 | NCT01001598 (ClinicalTrials.gov) | November 2009 | 22/10/2009 | Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita | Phase I/II Dose Escalation Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita | Fanconi Anemia;Dyskeratosis Congenita | Drug: danazol | Boston Children's Hospital | NULL | Terminated | 3 Years | N/A | All | 5 | Phase 1/Phase 2 | United States |
285. ファンコニ貧血
臨床試験数 : 62 / 薬物数 : 93 - (DrugBank : 30) / 標的遺伝子数 : 30 - 標的パスウェイ数 : 144
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01001598 (ClinicalTrials.gov) | November 2009 | 22/10/2009 | Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita | Phase I/II Dose Escalation Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita | Fanconi Anemia;Dyskeratosis Congenita | Drug: danazol | Boston Children's Hospital | NULL | Terminated | 3 Years | N/A | All | 5 | Phase 1/Phase 2 | United States |